Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Faster, Cleaner, Better.

Reata Pharma (RETA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

Cash Flow for [[ item.sessionDateDisplayLong ]]

Help

Go To:

Fiscal Year End Date: 12/31

(Values in U.S. thousands)

Previous Next

	12-2017	12-2016	12-2015	12-2014	12-2006
Cash Flows From Operating Activities
Net Income	-47,671	-6,227	-1,450	689	N/A
Depreciation Amortization	575	682	1,819	2,512	N/A
Income taxes - deferred	N/A	N/A	17,802	18,316	N/A
Accounts payable and accrued liabilities	-1,763	299	2,754	-1,656	N/A
Other Working Capital	-42,690	-16,081	-64,868	-111,873	N/A
Other Operating Activity	8,293	2,068	-677	3,382	0
Operating Cash Flow	$-83,256	$-19,259	$-44,620	$-88,630	$N/A

Cash Flows From Investing Activities
PPE Investments	-344	-340	-272	-183	N/A
Net Acquisitions	1	1	12	43	N/A
Investing Cash Flow	$-343	$-339	$-260	$-140	$N/A

Cash Flows From Financing Activities
Debt Issued	20,000	265	N/A	N/A	N/A
Debt Repayment	N/A	-45	-45	N/A	N/A
Common Stock Issued	109,570	64,709	39	N/A	N/A
Other Financing Activity	-923	-2,607	-864	1	0
Financing Cash Flow	$128,647	$62,322	$-870	$1	$N/A

Beginning Cash Position	84,732	42,008	87,758	176,527	N/A
End Cash Position	129,780	84,732	42,008	87,758	N/A
Net Cash Flow	$45,048	$42,724	$-45,750	$-88,769	$N/A

Free Cash Flow
Operating Cash Flow	-83,256	-19,259	-44,620	-88,630	N/A
Capital Expenditure	-344	-340	-272	-183	N/A
Free Cash Flow	-83,600	-19,599	-44,892	-88,813	0